More than half of 'new' drugs are no better than established treatments

Mail Online | 7/9/1999 | Alexandra Thompson Senior Health Reporter For Mailonline
abbycraigabbycraig (Posted by) Level 3
Click For Photo:

More than half of 'new' drugs are no better than established treatments, research suggests.

A study assessed the more than 200 medications that entered the German market between 2011 and 2017, many of which were approved for use across Europe.

Quarter - Benefit - Drugs

Only a quarter of these were judged to have a 'considerable or major added benefit' over the drugs that are already available.

These benefits may relate to a lower risk of early death, reduced symptoms or an improvement in quality of life.

Cent - Treatments - Evidence - Drugs - Equivalents

For 125 (58 per cent) of the treatments, there was insufficient evidence to prove the drugs were any better than already-available equivalents, the study found.

The research was carried out by the technology assessment agency IQWiG in Germany and led by Dr Beate Wieseler, head of the department of drug assessment.

Drugs - EU

All drugs must be authorised before they can be made in the EU.

The European Medicines Agency (EMA) assesses a treatment by looking at information collected from laboratory tests and clinical trials.

Benefits - Medication - Risks - EMA - Commission

If the benefits of a medication are deemed to be greater than its risks, the EMA recommends it to the European Commission for marketing across the EU and the European Economic Area, which includes the EU27 and Iceland and Norway.

The Food and Drug Administration (FDA), which regulates drugs in the US, has a similar system.

Approval - Development - Drug - Patients - Researchers

The approval and development of a drug may be sped up if it is thought to benefit patients, the researchers wrote in The BMJ.

But research dating back to the 1970s suggests only a limited number of these accelerated treatments are any better than existing options.

Extent - IQWiG - Drugs - Market

To better understand the extent of this, the IQWiG looked at the 216 drugs that entered the German market between 2011 and 2017.

By law, the IQWiG must investigate the added benefits of new drugs over standard care by looking at 'evidence contained in the...
(Excerpt) Read more at: Mail Online
Wake Up To Breaking News!
Have you forgotten?
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!